Biotech Startups

CWS Cleanrooms (CWS-STAXS) provides integrated contamination control for regulated manufacturers, managing cleanroom garments, cleaning, consumables, training and on-site support as a single validated programme. It serves life sciences (pharmaceutical, medical device) and semiconductor manufacturers across Europe, operating nine cleanroom textile facilities.

1 investor

Cx Precision Medicine develops blood-based diagnostic tests for Alzheimer's and other neurodegenerative diseases, delivering precision medicine tools for early diagnosis and personalized treatment in primary care settings.

1 investor

Cyagen provides preclinical research services including cell and animal model development, viral packaging, and expert-led preclinical studies to support IND applications. It serves life science researchers and biopharmaceutical organizations in drug development.

1 investor

CyanoCapture develops a synthetic biology platform using genetically engineered photosynthetic cells that convert CO2 into high-value molecules such as enzymes, growth factors, peptides, bioplastics, and drug compounds. The company targets biomanufacturing and critical supply chain applications through a zero-sugar, CO2-based production process.

1 investor

Cyanomin develops a biological desalination process that uses bacteria with electrically charged biofilms to adsorb and remove ions from hypersaline brines, treating wastewater without membranes, pressure, or heat. It serves industries that generate hypersaline wastewater, including oil & gas, lithium and copper extraction, and seawater desalination.

1 investor

Bio Green Med Solution is a diversified company operating in fire protection and biopharmaceutical sectors, with headquarters in Malaysia and a portfolio spanning pharmaceutical R&D and fire protection products and services.

1 investor

Cyclarity Therapeutics develops engineered cyclodextrin drugs that target and remove toxic oxidized cholesterol (7-ketocholesterol) to treat atherosclerosis and other age-related diseases. Its lead candidate, UDP-003, is a preclinical/early clinical therapy aimed at cardiovascular disease, with additional pipeline programs for stroke recovery, Alzheimer's, and other conditions.

1 investor

Cycle0 is a vertically integrated developer, investor, builder, and operator of biomethane plants across Europe that converts waste into renewable natural gas to reduce carbon emissions. The company serves agriculture, waste, food, and water sector organizations seeking renewable energy solutions and emissions reductions.

1 investor

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device. It targets patients, providers, and health systems seeking individualized mental health treatment.

1 investor

Cyclicor is a biotechnology company based in Lund, Sweden that develops sustainable alternatives for plastics and coatings. The company focuses on transitioning the chemical industry toward circular economy solutions.

1 investor

Cyclotek manufactures and distributes PET radiopharmaceuticals and radioactive medical devices for hospitals, research institutions, and clinical partners across Australia and New Zealand. The company provides GMP manufacturing, supply chain coordination, and translational support to enable molecular imaging diagnostics and therapy.

1 investor

Cycuria Therapeutics develops engineered biologics to treat blood cancers, targeting leukemic cells and their progenitor stem cells while sparing healthy blood formation, with an initial focus on Acute Myeloid Leukemia (AML). Its lead program is CUR-101, aimed at patients including older or unfit individuals who cannot tolerate intensive chemotherapy or stem cell transplants.

1 investor

Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation. Made by CyDex Pharmaceuticals (a Ligand company), it is used in approved therapeutics including remdesivir and carfilzomib, and is also explored for consumer health, supplements, and personal care products.

1 investor

Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. Its lead candidate, APL-130277, is a sublingual formulation of apomorphine intended as an alternative to subcutaneous injection, and had entered Phase 3 clinical development.

1 investor

CynosBio develops and commercializes regenerative medicine products, including cell-based treatments for cartilage damage, joint disorders, and liver disease. The company is based in Japan and pursues global expansion, particularly in the United States.

1 investor

cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators. The company focuses on accessible, scalable treatment using aerodynamically engineered nanoparticle delivery.

1 investor

Cyta Therapeutics develops polymer-based nanogel therapeutics (IntelliGels) to treat obesity, NASH, type 2 diabetes, and metabolic disorders. The company's lead program, Cyta-001, is a liver-targeted drug delivery system encapsulating a thyroid hormone receptor agonist for metabolic disease management.

1 investor

Cytecom develops a rapid diagnostic technology that detects viable bacteria in under a minute using a patented method of Optical Electrophysiology, combining fluorescent microscopy with electrical stimulation. The technology is aimed at addressing antimicrobial resistance through faster antibiotic susceptibility testing.

1 investor

CyteSi builds a semiconductor-based Bio Processing Unit (BPU) that creates a software-defined wet lab, using a programmable continuous-flow system to automate liquid-handling workflows such as NGS library prep, drug discovery, and reagent synthesis. The platform is aimed at labs and AI-driven research teams seeking high-throughput physical validation with reduced reagent use.

1 investor

CytoBioscience develops automated patch clamp instruments (CytoPatch) and offers contract research organization (CRO) services, cell lines, and consumables for electrophysiology and ion channel research. It serves pharmaceutical and life science research customers.

1 investor

1 investor

Cytodyme builds software for regulatory and quality teams at life science companies to manage post-market reporting, literature reviews, documentation, audits, and submissions. The platform consolidates data from disconnected systems to reduce administrative burden for regulated life science and biotech teams.

1 investor

1 investor

Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function. The company specializes in sarcomere-directed therapies targeting conditions involving muscle weakness, loss, and dysfunction.

1 investor